Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation

Journal of Pharmaceutical Sciences

Volumn 98, Issue 2, 2009, Pages 628-639

  Changsan, Narumon ^a   Chan, Hak Kim ^b   Separovic, Frances ^c   Srichana, Teerapol ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dry powder inhaler; Liposome; Molecular orientation; Rifampicin; Solid state NMR; Stability

Indexed keywords

CHOLESTEROL; LIPOSOME; PHOSPHATIDYLCHOLINE; RIFAMPICIN; ANTIINFECTIVE AGENT; CRYOPROTECTIVE AGENT; MANNITOL;

AEROSOL; ARTICLE; CRYOELECTRON MICROSCOPY; DEUTERON NUCLEAR MAGNETIC RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRY POWDER; ENCAPSULATION; FREEZE DRYING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHOTON CORRELATION SPECTROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; TUBERCULOSIS; X RAY DIFFRACTION; CHEMISTRY; DRUG STABILITY; INHALATIONAL DRUG ADMINISTRATION; PARTICLE SIZE; PHARMACEUTICS; POWDER; TEMPERATURE; TIME;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; CRYOPROTECTIVE AGENTS; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; LIPOSOMES; MANNITOL; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; POWDERS; RIFAMPIN; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TIME FACTORS;

EID: 59849109942     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21441     Document Type: Article

References (36)

1. American Hospital Formulary Society. 1999. Antituberculosis agents. Bethesda, MD: American Hospital Formulary Society Drug Information, pp 464-502.
2. Suarez S, Hickey AJ. 2000. Drug properties affecting aerosol behavior. Respir care 45:652-664.
3. Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13:238-252.
4. Couvreur P, Fattal E, Andremont A. 1991. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res 8:1079-1086.
5. Lasic DD. 1998. Novel applications of liposomes. Tibtech 16:307-321.
6. Mehta RT, Keyhani A, McQueen TJ, Rosenbaum B, Rolston KV, Tarrand JT. 1993. In vitro activities of free and liposomal drugs against Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother 37:2584-2587.
7. Deol P, Khuller GK. 1997. Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1334:161-172.
8. Deol P, Khuller GK, Joshi K. 2001. Therapeutic efficacies of isoniazid and rifampicin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 41:1211-1214.
9. Labana S, Pandey R, Sharma S, Khuller GK. 2002. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents 20:301-304.
10. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. 2004. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophage. Int J Pharm 269:37-49.
11. Khuller GK, Kapur M, Sharma S. 2004. Liposome technology for drug delivery against Mycobacterial infections. Curr Pharm Des 10:3263-3274.
12. Gallo GG, Radaelli P. 1976. Rifampicin. In: Florey K, editor. Analytical profiles of drug substances, Vol. 5. New York: Academic Press, Inc. pp 468-513.
13. Hu C, Rhodes DG. 1999. Proniosomes: A novel drug carrier preparation. Int J Pharm 185:23-35.
14. 31P-NMR and DSC study. Colloids Surf A Physicochem Eng Asp 158:59-66.
15. Rodrigues C, Gameiro P, Prieto M, Castro B. 2003. Interaction of rifampicin and isoniazid with large unilamellar liposomes:spectroscopic location studies. Biochim Biophys Acta 1620:151-159.
16. Vemuri S, Rhodes CT. 1995. Preparation and characterization of liposomes as therapeutic delivery systems: A review. Pharm Acta Helv 70:95-111.
17. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. 2007. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 67:655-666.
18. Frederik PM, Hubert DHW. 2005. Cryoelectron microscopy of liposomes. Methods Enzymol 391:431-448.
19. Calleri E, Lorenzi ED, Furlanetto S, Massolini G, Caccialanza G. 2002. Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation. J Pharm Biomed 29:1089-1096.
20. Drechsler A, Separovic F. 2003. Solid-state NMR structure determination. IUBMB Life 55:515-523.
21. 2H NMR. Biochim Biophys Acta 737:117-171.
22. Winden ECA, Zhang W, Crommelin DJA. 1997. Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration. Pharm Res 14:1151-1160.
23. Morris KR, Rodriguez-Hornedo N. 1993. Hydrates. In: Swarbrick J, Boyland JC, editors. Encyclopedia of pharmaceutical technology, Vol. 7. New York: Marcel Dekker Inc. pp 393-440.
24. US Pharmacopeial Convention, Inc. 2000. US Pharmacopeia 24 -NF19. Rockville, MD: US Pharmacopeial Convention, Inc. pp 1899-1900.
25. Atkins PJ, Barker NP, Mathisen D. 1992. The design and development of inhalation drug delivery system. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker Inc. pp 155-185.
26. Srichana T, Suedee R, Srisudjai P. 2003. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie 58:125-129.
27. New RRC. 1990. Introduction. In: New RRC, editor. Liposomes: A practical approach. New York: IRL Press. pp 1-32.
28. Cornell BA, Weir LE, Separovic F. 1988. The effect of gramicidin A on phospholipid bilayers. Eur Biophys J 16:113-119.
29. Cornell BA, Separovic F. 1988. A model for gramicidin A phospholipid interactions in bilayers. Eur Biophys J 16:299-306.
30. Thewalts JL, Bloom M. 1992. Phosphatidylcholine: Cholesterol phase diagram. Biophys J 63:1176-1181.
31. Cortes FV, Caekenberghe DV. 1997. Glassification and its applications. Ann Med Mill Belg 11:17-23.
32. Pikal MJ. 1999. Impact of polymorphism on the quality of lyophilized products. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker Inc. pp 395-419.
33. Separovic F, Lam YH, Ke X, Chan H-K. 1998. A solid-state NMR study of protein hydration and stability. Pharm Res 15:1816-1821.
34. Steele G. 2001. Preformulation as an aid to product design in early drug development. In: Gibson M, editor. Pharmaceutical preformulation and formulation: A practical guide from candidate drug selection to commercial dosage form. New York: IHS® Health Group. pp 175-237.
35. Lam Y-H, Bustami R, Phan T, Chan H-K, Separovic F. 2002. A solid-state NMR study of protein mobility in lyophilised protein-sugar powders. J Pharm Sci 91:943-951.
36. Sun WQ, Leopold AC, Crowe LM, Crowe JH. 1996. Stability of dry liposomes in sugar glasses. Biophys J 70:1769-1776.